دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Melanoma medicine in the new millennium
H. Tsao
doi : 10.1111/bjd.20420
Volume 185, Issue 2 p. 239-240
Total body photography for secondary prevention of melanoma
H. Kittler
doi : 10.1111/bjd.20058
Volume 185, Issue 2 p. 241-241
In theory, total body photography (TBP) improves early recognition of melanoma because it facilitates the detection of small melanomas. In practice, TBP may also have undesirable effects, such as an inflation in the number of surgical procedures for benign lesions. In their excellent systematic review published in this issue of the BJD, Ji-Xu et al. provide summary estimates of the number needed to biopsy (NNB) of TBP for the diagnosis of melanoma in high-risk individuals.1
Tildrakizumab: interpreting the data
C.G. Purvis,V.K. Emmerich,S.R. Feldman,
doi : 10.1111/bjd.20430
Volume 185, Issue 2 p. 242-243
Association of atopic dermatitis and autoimmune comorbidities: is it real?
J.I. Silverberg
doi : 10.1111/bjd.20497
Volume 185, Issue 2 p. 243-244
Increased cutaneous squamous cell carcinoma risk with hydrochlorothiazide use: is there a safe alternative?
L.M. Hollestein,S. Arnspang Pedersen,
doi : 10.1111/bjd.20526
Volume 185, Issue 2 p. 244-245
Multiple studies have shown that hydrochlorothiazide, a photosensitizing drug, increases the risk of skin cancer.1-6 In this issue of the BJD, Schneider et al. confirm the strongly increased risk of cutaneous squamous cell carcinoma (cSCC) in a cohort study using a UK primary care database.7 Although, weak associations with melanoma and basal cell carcinoma (BCC) have been observed in some studies, these were not observed in the cohort study of Schneider et al.7
Is consumption of citrus associated with a higher risk of melanoma?
Y. Mahamat-Saleh
doi : 10.1111/bjd.20408
Volume 185, Issue 2 p. 245-246
Yet another benefit from sunlight in the fight against COVID-19?
R.L. McKenzie,J.B. Liley,
doi : 10.1111/bjd.20516
Volume 185, Issue 2 p. 246-247
A paper in this issue of the BJD shows significant associations between deaths from COVID-19 and ambient ultraviolet (UV) A radiation.1 The study focuses on the USA, but finds that the association is also present in Italy and England, despite large differences in their mortality rates. The statistical analysis is restricted to the initial 3 months of the pandemic, and to regions where the production of vitamin D from sunlight in that winter period is small. The authors argue that regional differences in the levels of UVA promote variations in the release of nitric oxide from the skin, and postulate that the elevated levels of nitric oxide led to better health outcomes through its ability to lower blood pressure, and through its possible effects on the ability of SARS-CoV-2 to self-replicate.
One set to collect them all? The development of a core domain set for medium-to-giant congenital melanocytic naevi
M.V. Heppt,T. Steeb,C. Berking,
doi : 10.1111/bjd.19878
Volume 185, Issue 2 p. 247-248
Large, giant or multiple congenital melanocytic naevi (CMN) are associated with an increased risk of developing melanoma or symptomatic neurocutaneous melanocytosis.1, 2 In addition to close clinical observation, treatment options comprise laser ablation, curettage or surgery, with which complete excision is often difficult to achieve. While surgical removal improves the cosmetic appearance,3-5 the risk of malignant transformation cannot be completely eliminated, as melanomas may arise in deeper dermal or extracutaneous sites such as the central nervous system. Treatment recommendations are still controversial due to lack of evidence-based guidelines and due to the heterogeneity of outcome assessment in patient care and trial reporting. To this end, it is increasingly recognized that harmonization of outcomes has widely been neglected. To promote the standardization of outcomes and their use in dermatology, the Core Outcome Measures in Effectiveness Trials (COMET) and the Cochrane Skin – Core Outcome Set Initiative (CS-COUSIN) were established.6 Currently, 63 dermatology-related projects are registered, including studies on 34 different skin conditions.7
Another twist of the allogenic haematopoietic cell transplantation story
J.W. Bauer
doi : 10.1111/bjd.20478
Volume 185, Issue 2 p. 248-249
Novel light-dependent and light-independent functions of opsin 5
L.V.M. de Assis,A.M.L. Castrucci,
doi : 10.1111/bjd.20052
Volume 185, Issue 2 p. 249-250
The time for new biomarkers in mycosis fungoides/Sézary syndrome is here
P.L. Ortiz-Romero
doi : 10.1111/bjd.20491
Volume 185, Issue 2 p. 250-251
Differentiation between early mycosis fungoides (MF) and benign inflammatory dermatoses (BID) is not easy. It is usually based on clinicopathological, immunohistochemical and molecular (T-cell receptor rearrangement) studies, but frequently requires multiple biopsies over several years before a final diagnosis is reached.1
Is lymph node core-needle biopsy an alternative to excisional biopsy for the accurate staging of mycosis fungoides/Sézary syndrome and predicting the survival of patients?
E. Hodak
doi : 10.1111/bjd.20496
Volume 185, Issue 2 p. 251-252
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
X. Bai,K.T. Flaherty,
doi : 10.1111/bjd.19394
Volume 185, Issue 2 p. 253-262
Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
A. Gault,A.E. Anderson,R. Plummer,C. Stewart,A.G. Pratt,N. Rajan,
doi : 10.1111/bjd.19750
Volume 185, Issue 2 p. 263-271
Melanoma genomics: a state-of-the-art review of practical clinical applications*
S. Guhan,N. Klebanov,H. Tsao,
doi : 10.1111/bjd.20421
Volume 185, Issue 2 p. 272-281
Melanoma pathology: new approaches and classification*
I. Yeh,B.C. Bastian,
doi : 10.1111/bjd.20427
Volume 185, Issue 2 p. 282-293
Melanoma-associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target*
M. Perez,A. Chakraborty,L.S. Lau,N.B.B. Mohammed,C.J. Dimitroff,
doi : 10.1111/bjd.19891
Volume 185, Issue 2 p. 294-301
Total body photography for the diagnosis of cutaneous melanoma in adults: a systematic review and meta-analysis*
A. Ji-Xu,J. Dinnes,R.N. Matin,
doi : 10.1111/bjd.19759
Volume 185, Issue 2 p. 302-312
Oral corticosteroid bursts and severe adverse events: a critical appraisal
S.-C. Shao,L.-T. Kuo,E. C.-C. Lai,C.-C. Chi,
doi : 10.1111/bjd.20071
Volume 185, Issue 2 p. 313-314
A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*
C. Abels,M. Soeberdt,A. Kilic,H. Reich,U. Knie,C. Jourdan,K. Schramm,S. Heimstaedt-Muskett,C. Masur,R.-M. Szeimies,
doi : 10.1111/bjd.19810
Volume 185, Issue 2 p. 315-322
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*
D. Thaci,S. Piaserico,R.B. Warren,A.K. Gupta,W. Cantrell,Z. Draelos,P. Foley,A. Igarashi,R.G. Langley,A. Asahina,M. Young,M. Falqués,I. Pau-Charles,A.M. Mendelsohn,S.J. Rozzo,K. Reich
doi : 10.1111/bjd.19866
Volume 185, Issue 2 p. 323-334
Association between atopic dermatitis and autoimmune diseases: a population-based case–control study*
L.U. Ivert,C.-F. Wahlgren,B. Lindel?f,H. Dal,M. Bradley,E.K. Johansson,
doi : 10.1111/bjd.19624
Volume 185, Issue 2 p. 335-342
Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group*
R. Schneider,D. Reinau,S. Stoffel,S.S. Jick,C.R. Meier,J. Spoendlin,
doi : 10.1111/bjd.19880
Volume 185, Issue 2 p. 343-352
The association between citrus consumption and melanoma risk in the UK Biobank*
A.R. Marley,M. Li,V.L. Champion,Y. Song,J. Han,X. Li,
doi : 10.1111/bjd.19896
Volume185, Issue 2 p. 353-362
Ultraviolet A radiation and COVID-19 deaths in the USA with replication studies in England and Italy*
M. Cherrie,T. Clemens,C. Colandrea,Z. Feng,D.J. Webb,R.B. Weller,C. Dibben,
doi : 10.1111/bjd.20093
Volume 185, Issue 2 p. 363-370
Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research*
W. Oei,A.C. Fledderus,P.I Spuls,C.A.M. Eggen,J. Kottner,C.M.A.M. van der Horst,A. Wolkerstorfer,M.S. van Kessel,S. Krengel,H.C. Etchevers,I.J. Korfage,S.G.M. Pasmans,
doi : 10.1111/bjd.19694
Volume185, Issue 2 p. 371-379
Fludarabine modulates expression of type VII collagen during haematopoietic stem cell transplantation for recessive dystrophic epidermolysis bullosa*
M. Vanden Oever,D. Muldoon,W. Mathews,J. Tolar,
doi : 10.1111/bjd.19757
Volume 185, Issue 2 p. 380-390
Opsin 5 is a key regulator of ultraviolet radiation-induced melanogenesis in human epidermal melanocytes*
Y. Lan,W. Zeng,X. Dong,H. Lu,
doi : 10.1111/bjd.19797
Volume 185, Issue 2 p. 391-404
The value of five blood markers in differentiating mycosis fungoides and Sézary syndrome: a validation cohort*
G. Dobos,C. De Cevins,S. Ly Ka So,F. Jean-Louis,S. Mathieu,C. Ram-Wolff,M. Resche-Rigon,A. Bensussan,M. Bagot,L. Michel,
doi : 10.1111/bjd.19719
Volume 185, Issue 2 p. 405-411
Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort*
M.A. El Sharouni,A.H.R. Varey,A.J. Witkamp,T. Ahmed,V. Sigurdsson,P.J. van Diest,R.A. Scolyer,J.F. Thompson,S.N. Lo,C.H. van Gils,
doi : 10.1111/bjd.19895
Volume 185, Issue 2 p. 412-418
Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndrome*
J. Calvani,A. de Masson,C. de Margerie-Mellon,?. de Kerviler,C. Ram-Wolff,A. Gruber,V. Meignin,P. Brice,A. Sadoux,S. Mourah,M. Bagot,M. Battistella,
doi : 10.1111/bjd.19796
Volume 185, Issue 2 p. 419-427
Antiracism plan in dermatology
C. Ortiz,E. Herman,A.J. James,
doi : 10.1111/bjd.20390
Volume 185, Issue 2 p. 428-429
Differences in the clinical presentation of bullous pemphigoid in patients with skin of colour and patients with white skin
P. Shah,K. Svigos,L. Yin,N. Soter,K. Lo Sicco,P. Adotama,
doi : 10.1111/bjd.20068
Volume 185, Issue 2 p. 430-432
Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report
F.N. Mirza,A. Wang,S.M. Ramachandran,W. Damsky,J.M. Cohen,
doi : 10.1111/bjd.20064
Volume 185, Issue 2 p. 432-434
Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020
R. Ottevanger,D.T. de Bruin,R. Willemze,P.M. Jansen,M.W. Bekkenk,E.R.M. de Haas,B. Horvath,M.M. van Rossum,C.J.G. Sanders,J.C.J.M. Veraart,M.H. Vermeer,K.D. Quint,
doi : 10.1111/bjd.20048
Volume 185, Issue 2 p. 434-435
New recommendations for retinal monitoring in hydroxychloroquine users: baseline testing is no longer supported
I.H. Yusuf,F. Latheef,M. Ardern-Jones,A.J. Lotery,
doi : 10.1111/bjd.20073
Volume 185, Issue 2 p. 435-438
Reliability and meaningful change of the Patient-Reported Outcomes Measurement Information System® Itch Questionnaire (PIQ) item banks in adults with atopic dermatitis
J.I. Silverberg,J.-S. Lai,D. Cella,
doi : 10.1111/bjd.20066
Volume 185, Issue 2 p. 438-439
Additional causal SNRPE mutations in hereditary hypotrichosis simplex
C. Pan,A. Humbatova,L. Zheng,N. Cesarato,C. Grimm,F. Chen,B. Blaumeiser,A. Catal?n-Lamb?n,A. Pati?o-Garc?a,U. Fischer,R. Cheng,Y. Li,X. Yu,Z. Yao,M. Li,R.C. Betz
doi : 10.1111/bjd.20089
Volume 185, Issue 2 p. 439-441
Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study
Z.Z.N. Yiu,G. Harding-Oredugba,C.E.M. Griffiths,R.B. Warren,E. McMullen,H.J.A. Hunter,
doi : 10.1111/bjd.20062
Volume 185, Issue 2 p. 441-443
The association between schizophrenia spectrum disorders and psoriasis: a large-scale population-based case–control study
A.F. Carvalho,M.O. Machado,E. Mallia,X. Liu,L. Eder,M. Solmi,V. Piguet,P. Kurdyak,
doi : 10.1111/bjd.20094
Volume 185, Issue 2 p. 443-445
Pernio after COVID-19 vaccination
S. Lopez,P. Vakharia,T. Vandergriff,E.E. Freeman,R. Vasquez,
doi : 10.1111/bjd.20404
Volume 185, Issue 2 p. 445-447
Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria
M.L. Ramien,A. Bahubeshi,I. Lara-Corrales,E. Pope,M.L. Levy,A.J. Nopper,N.H. Shear,L. Eichenfield,
doi : 10.1111/bjd.20063
Volume 185, Issue 2 p. 447-449
Clinical and immunological findings in 55 patients with anti-laminin 332-type mucous membrane pemphigoid
X. Li,H. Qian,Y. Natsuaki,H. Koga,T. Kawakami,C. Tateishi,D. Tsuruta,N. Ishii,T. Hashimoto,
doi : 10.1111/bjd.20099
Volume 185, Issue 2 p. 449-451
Evaluating the World Health Organization Model List of Essential Medicines for skin disease
C.W. Rundle,A.P. Fortugno,J. Maghfour,C.L. Presley,K. Pulsipher,S.S. Husayn,L. Naldi,O. Chosidow,R. Hay,R.P. Dellavalle,
doi : 10.1111/bjd.20081
Volume 185, Issue 2 p. 451-453
Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL–1: why we should investigate further
F. Jendoubi,J. Shourick,M. Negretto,C. Laurent,P.A. Apoil,S. Evrard,V. Mansat-De Mas,M. Severino-Freire,C. Mailhol,Y. Degboé,P. Dubreuil,O. Hermine,C. Paul,C. Bulai Livideanu
doi : 10.1111/bjd.20098
Volume 185, Issue 2 p. 453-455
Development of clinical diagnostic criteria for chronic plaque psoriasis: an international e-Delphi study
M. Abo-Tabik,R. Parisi,S.C. Willis,C.E.M. Griffiths,D.M. Ashcroft,on behalf of the Global Psoriasis Atlas (GPA),
doi : 10.1111/bjd.20096
Volume 185, Issue 2 p. 455-456
Automated detection of skin reactions in epicutaneous patch testing using machine learning
W.H. Chan,R. Srivastava,N. Damaraju,H. Do,G. Burnett,J. MacFarlane,S.M. Xie,J.K. Chen,G. Honari,K.Y. Sarin,
doi : 10.1111/bjd.20141
Volume 185, Issue 2 p. 456-458
Efficacy of S-1 plus docetaxel in the treatment of metastatic extramammary Paget’s disease: a multicentre retrospective study
S. Matsushita,K. Fujii,I. Kajihara,M. Aoki,K. Yamamura,K. Tada,T. Kanekura,J. Aoi,S. Fukushima,
doi : 10.1111/bjd.20135
Volume 185, Issue 2 p. 458-460
The impact of the COVID-19 pandemic on skin cancer incidence and treatment in England, 2020
Z. C. Venables,S. Ahmed,T. O. Bleiker,J. Broggio,M. Kwiatkowska,N. J. Levell,G. W. M. Millington,L. Paley,E. Payne,C. M. Proby,S. Vernon,S. McPhail,
doi : 10.1111/bjd.20409
Volume 185, Issue 2 p. 460-462
Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours
B.L.M. Ykema,F. Adan,M.B. Crijns,F.E. Bleeker,E. Dekker,M.W. Bekkenk,P. Snaebjornsson,M.E. van Leerdam,
doi : 10.1111/bjd.20139
Volume 185, Issue 2 p. 462-463
Dupilumab-associated arthralgia: an observational retrospective study in VigiBase®
B. Chrétien,C. Dolladille,J. Alexandre,S. Fedrizzi,V. Lelong-Boulouard,J.C. Lambert,E. Ezine,
doi : 10.1111/bjd.20138
Volume 185, Issue 2 p. 464-465
Immediate global support is needed for Myanmar
S.M. Lwin,C.E.M. Griffiths,
doi : 10.1111/bjd.20385
Volume 185, Issue 2 p. 466-467
Pharmacokinetic profile data of glycopyrronium bromide 1% cream beyond 2 weeks are important
S. Gregoriou,G. Kontochristopoulos,E. Tiligada,
doi : 10.1111/bjd.20088
Volume 185, Issue 2 p. 467-468
Pharmacokinetic profile data of glycopyrronium bromide 1% cream beyond 2 weeks are important: reply from the authors
C. Abels,M. Soeberdt,A. Kilic,H. Reich,U. Knie,C. Masur,R.-M. Szeimies,
doi : 10.1111/bjd.20095
Volume 185, Issue 2 p. 468-469
Synergistic multiple early therapy (SMET) for inflammatory diseases with pathogenic autoinflammatory feedback circuits
J.P. McFadden,L.S. Cunningham,F.J. Ferguson,C. Tziotzios,J.A. McGrath,
doi : 10.1111/bjd.20077
Volume 185, Issue 2 p. 469-470
Professor Jean-Claude Roujeau (1944–2021)
R.S. Stern
doi : 10.1111/bjd.20076
Volume 185, Issue 2 p. 470-471
Pityriasis rosea-like eruption after Pfizer–BioNTech COVID-19 vaccination
A.M. Carballido V?zquez,B. Morgado,
doi : 10.1111/bjd.20143
Volume 185, Issue 2 p. e34-e34
COVID-19-associated multisystem inflammatory syndrome in adults with Kawasaki disease-like cutaneous manifestations
M. Razmi T,T.P. Afra,T.P. Mohammed,P.T.M. Ashik,E. Sukesh,
doi : 10.1111/bjd.20425
Volume 185, Issue 2 p. e35-e35
Does fludarabine have a beneficial effect in recessive dystrophic epidermolysis bullosa?
doi : 10.1111/bjd.20528
Volume 185, Issue 2 p. e36-e36
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disorder. Patients with RDEB experience severe painful blistering and skin fragility due to separation of two layers of the skin: the dermis and epidermis. This occurs because type VII collagen (C7) is deficient or absent in the skin. C7 is a major component responsible for tethering the epidermis to the dermis. The skin heals with disfiguring scarring, and patients are at risk of secondary infection and an aggressive form of squamous carcinoma, a type of skin cancer. There is currently no cure but there are encouraging results from some experimental treatments. One treatment is haematopoietic stem cell transplantion, where the engrafted cells appear to increase the amount of C7 (a process called deposition) over the long-term. Unfortunately, this treatment requires long term immunosuppression and this is particularly risky in patients with RDEB, who are prone to infections.
Consensus on outcomes for research and care of patients with congenital melanocytic naevi
doi : 10.1111/bjd.20529
Volume 185, Issue 2 p. e37-e37
Medium, large and giant congenital melanocytic naevi (CMN, pigmented moles present at birth or shortly afterwards) can have a psychological and social impact on patients and families. They are also associated with an increased risk of developing melanoma (a serious form of skin cancer) or neurological symptoms. Lack of agreement on what outcomes to measure makes it difficult to advise patients and families about treatment.
Blood markers in mycosis fungoides and Sézary syndrome
doi : 10.1111/bjd.20530
Volume 185, Issue 2 p. e38-e38
This study from Paris, France, looked at five substances (markers) in blood to see if they might help in the diagnosis of mycosis fungoides (MF) and Sézary syndrome (SS), types of lymphoma (an immune system cancer) that affect the skin. It can be difficult to separate these conditions from benign (non-cancerous) skin conditions and from each other. Early MF, for example, may resemble eczema or psoriasis, whereas severe MF can make the skin red and inflamed all over (a state known as erythroderma) – but erythroderma also occurs in SS, severe eczema and severe psoriasis. Special tests are therefore routinely performed on skin samples to try to distinguish MF and SS. In SS, where there are abnormal lymphocytes in the bloodstream, special tests are also performed on blood samples. There is room for improvement in these methods, hence this research looking at four markers previously reported as possibly helpful in SS and advanced or erythrodermic MF, and a fifth as possibly useful in early MF.
Findings from a large study investigating the association between atopic dermatitis and autoimmune diseases
doi : 10.1111/bjd.20531
Volume 185, Issue 2 p. e39-e39
Atopic dermatitis (AD) is one of the most common chronic skin disorders globally and causes dry skin and recurrent itchy lesions. The proportion of people who have AD during a 1-year period is about 17% among adults and 23% among children.
GPB cream reduces excessive underarm sweating
doi : 10.1111/bjd.20532
Volume 185, Issue 2 p. e40-e40
Approximately 5% of people worldwide suffer from permanent excessive sweating, so-called ‘primary hyperhidrosis’, which has a severe impact on their quality of life. Yet, more than 50% of all people with hyperhidrosis receive no treatment.
The role of opsin 5 in the skin’s response to ultraviolet radiation
doi : 10.1111/bjd.20533
Volume 185, Issue 2 p. e41-e41
The skin provides a protective barrier from the external environment. Human skin is constantly exposed to solar ultraviolet radiation (UVR). Solar UVR is known as the main factor for stimulating pigmentation of the skin. UVR-induced pigmentation is a protective response as a result of a process called melanogenesis in human epidermal melanocytes. This provides protection from UVR-induced damage. However, the molecular mechanisms used by human epidermal melanocytes to detect and respond to UVR are not fully understood.
Risk of skin cancer after starting treatment with hydrochlorothiazide or similar drugs to lower blood pressure
doi : 10.1111/bjd.20534
Volume 185, Issue 2 p. e42-e42
The main risk factors for the development of melanoma skin cancer and nonmelanoma skin cancer (consisting mainly of basal cell carcinoma, BCC, and squamous cell carcinoma, SCC) are exposure to sunlight and fair skin type. Two previous studies (from Denmark) have raised concern that long-term use of the drug hydrochlorothiazide (HCTZ) may increase the risk of skin cancer, most prominently the risk of SCC.
A useful tool to help predict survival in Sézary syndrome and mycosis fungoides
doi : 10.1111/bjd.20535
Volume 185, Issue 2 p. e43-e43
Mycosis fungoides (MF) and Sézary syndrome (SS) are both forms of lymphoma, a cancer of immune cells called lymphocytes. They are the most frequent cutaneous T-cell lymphoma. Predicting the likely outcome (the prognosis) of SS and MF depends on lymph node (gland) involvement. Establishing lymph node involvement is so important as cancer often spreads to nearby lymph nodes before it reaches other parts of the body.
A long-term study of tildrakizumab treatment in patients with psoriasis
doi : 10.1111/bjd.20536
Volume 185, Issue 2 p. e44-e44
Psoriasis, a common skin condition causing red and scaly patches of skin, affects about 2% of people worldwide. We wanted to see how effective and safe the drug tildrakizumab is for long-term psoriasis treatment.
Total body photography as an aid to diagnosing malignant melanoma
doi : 10.1111/bjd.20537
Volume 185, Issue 2 p. e45-e45
Melanoma accounts for 5% of skin cancer cases but up to 75% of skin cancer deaths. Early detection of melanoma can reduce morbidity and mortality. Total body photography (TBP) is increasingly used in patients at high risk of melanoma to help identify both suspicious new lesions and changes in pre-existing lesions.
Predicting the spread of a melanoma to other parts of the body
doi : 10.1111/bjd.20538
Volume 185, Issue 2 p. e46-e46
Melanoma is a serious form of skin cancer that arises when pigment cells in the skin become malignant (cancerous). During their lifetime melanoma develops in about 1 in 40 people in the UK and 1 in 20 people in Australia. Melanoma can spread to other parts of the body (i.e. ‘metastasize’), and when this occurs the person’s life is at serious risk.
An update on melanoma genomics
doi : 10.1111/bjd.20539
Volume 185, Issue 2 p. e47-e47
Melanoma is the most aggressive type of skin cancer. Immune-boosting therapies and targeted treatments have greatly improved survival for some but not all patients. Over the past 10 years genetic changes in melanomas have been recognized and are being used to classify melanomas and design targeted treatments. This American team from Harvard reviews the current state of knowledge.
The discovery of a new marker of melanoma progression
doi : 10.1111/bjd.20540
Volume 185, Issue 2 p. e48-e48
Melanoma is a type of skin cancer, which arises from the pigment cells (melanocytes) in the skin. Melanoma is considered to be the most serious type of skin cancer because it is more likely to spread (metastasize) from the skin to other parts of the body than other types of skin cancer. If melanoma has spread to other parts of the body, those deposits are known as secondary melanoma (secondaries/metastases).
A review of melanoma pathology – new approaches and classification
doi : 10.1111/bjd.20541
Volume 185, Issue 2 p. e49-e49
Recent work on the development of the malignant skin cancer, melanoma, and in particular finding new ways to classify lesions into specific types enables those treating patients to find the best methods of medical or surgical management. But it is very dependent on the use of modern investigative tools, known as molecular techniques, that allow investigators to identify genetic abnormalities or mutations in each lesion. This provides a useful picture of the likely behaviour of the tumour.
Citrus products and risk of getting melanoma
doi : 10.1111/bjd.20542
Volume 185, Issue 2 p. e50-e50
Melanoma is the most serious form of skin cancer, and people all over the world have been getting it more and more in recent decades. In the UK, melanoma is the fifth most common cancer diagnosis.
Sunlight separately from vitamin D is associated with a lower risk of death from COVID-19
doi : 10.1111/bjd.20543
Volume 185, Issue 2 p. e51-e51
Many infectious diseases vary from season to season. We set out to discover whether sunlight might affect the risk of death from COVID-19, and whether this might occur independently of vitamin D production.
?????????????????????????????
doi : 10.1111/bjd.20544
Volume 185, Issue 2 p. e52-e52
??????????????? (RDEB) ???????????RDEB ???????? (?????) ??????????????????????????????? VII ??? (C7) ???C7 ????????????????????????????????, ?????????????????? (?????) ????????????, ?????????????????????????????????????, ??????????????C7??? (?????????) ?????, ??????????????, ??????? RDEB ???????
????????????????????
doi : 10.1111/bjd.20545
Volume 185, Issue 2 p. e53-e53
???????????????? (CMN, ???????????????) ???????????????????????????? (????????) ???????????????????????????, ??????????????????
?????? Sézary ?????????
doi : 10.1111/bjd.20546
Volume 185, Issue 2 p. e54-e54
?????????????????? 5 ??? (???) , ???????????????? (MF) ? Sézary ??? (SS), ??????????? (????????) ??????????????? (???) ???????, ?????????????????, ?? MF ???????????, ??? MF ??????????? (??????????) , ????????? SS??????????????, ??????????????, ????? MF ? SS?? SS ?, ?????????????, ????????????????????????, ?????????????????? SS ???????? MF ? 4 ????, ??? 5 ??????????? MF ?????
?????????????????????????????
doi : 10.1111/bjd.20547
Volume 185, Issue 2 p. e55-e55
????? (AD) ??????????????, ???????????????????????? 1 ????? AD ??????? 17% ? 23%?
???? (GPB) ?????????
doi : 10.1111/bjd.20548
Volume 185, Issue 2 p. e56-e56
????? 5% ????????? (??“??????”) , ???????????????????, 50% ??????????????
??? 5 ????????????????
doi : 10.1111/bjd.20549
Volume 185, Issue 2 p. e57-e57
??????????????????????????????????? (UVR) ???? UVR ??????????????????UVR ??????????????????????????????????????????? UVR ????????, ?????????????? UVR ????????????
???????????????????????
doi : 10.1111/bjd.20550
Volume 185, Issue 2 p. e58-e58
???????????????? (????????? [BCC] ?????? [SCC]) ?????????????????????????? (????) ????????, ???????? (HCTZ) ???????????????, ????????? SCC ????
??????? Sézary ?????????????????
doi : 10.1111/bjd.20551
Volume 185, Issue 2 p. e59-e59
????? (MF) ? Sézary ??? (SS) ??????, ??????????????????????????? T ???????? SS ? MF ????? (??) ?????? (??) ??????????????????, ?????????????????????????????
????????? Tildrakizumab ???????
doi : 10.1111/bjd.20552
Volume 185, Issue 2 p. e60-e60
?????????????, ?????????????, ???? 2% ????????????????? Tildrakizumab ??????????????????
???????????????????
doi : 10.1111/bjd.20553
Volume 185, Issue 2 p. e61-e61
?????????? 5%, ?????????? 75%??????????????????????? (TBP) ???????????????, ????????????????????
??????????????
doi : 10.1111/bjd.20554
Volume 185, Issue 2 p. e62-e62
????????????, ????????????? (??) ?????????????, ? 40 ???? 1 ??????; ?????, ? 20 ???? 1 ????????????????????? (?“??”) , ???????, ?????????????
????????????
doi : 10.1111/bjd.20555
Volume 185, Issue 2 p. e63-e63
????????????????????????????????????? (?????) ???????? 10 ??, ??????????????, ????????????????????????????????????????
?????????????
doi : 10.1111/bjd.20556
Volume 185, Issue 2 p. e64-e64
?????????, ????????? (????) ???????????????????, ???????????????????? (??) ??????????????????????????, ??????????????? (??/??)?
???????? – ??????
doi : 10.1111/bjd.20557
Volume 185, Issue 2 p. e65-e65
????????????????????, ???????????????????, ???????????????????????, ??????????????????????????????????? (??????) ???????????????????
?????????????
doi : 10.1111/bjd.20558
Volume 185, Issue 2 p. e66-e66
?????????????, ?????, ????????????????????, ??????????????
???????????????, ???????? D
doi : 10.1111/bjd.20559
Volume 185, Issue 2 p. e67-e67
???????????????????????????????????????, ??????????? D ?????
